Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
1 2 3 4 5 6 Next › Last »

Prevision Policy Clips | COVID Treatment Prices are "Reasonably Aligned" With Patient Benefit, Per ICER

March 28, 2022

FDA Pursuing More Partnerships On Artificial Intelligence; CDRH Director Shuren Says Contact With Collaborative Communities Will Be “Business As Usual”

March 25, 2022

Prevision Policy Clips | Single-Arm Trial For PI3K Inhibitor Zandelisib Not Sufficient For Accelerated Approval, FDA Tells Sponsors

March 25, 2022

Revamped Division Of Neurology 1, Peripheral & CNS Advisory Committee Under Spotlight For ALS Drug Review

March 24, 2022

Biosimilars User Fee Program “Working Well” And Growing, FDA Says; Teva Calls For Better Communication On Inspections

March 24, 2022

Prevision Policy Clips | China-Only Data Application For Lilly/Innovent’s Sintilimab Receives FDA Complete Response Letter

March 24, 2022

Prevision Policy Clips | FDA COVID Vaccine Efficacy Guidance Could Be Tested With Moderna EUA Request For Children Under Six

March 23, 2022

Prevision Policy Clips | CBER “Actively Working” On Office Of Vaccine Research & Review Leadership Vacancies, FDA Says

March 22, 2022

FDA Oncology Center Coordinates Safety Signal Assessments To Assure Consistency Across Drug Classes; “Project Protect” Featured In Annual Report

March 21, 2022

Prevision Policy Clips | COVID Booster Vaccine FDA Advisory Committee Set For April 6, But “No Vote” On Product-Specific Applications

March 21, 2022

FDA Hiring Process And Results Continue To Improve, External Assessment Indicates, But More Coordination Needed

March 18, 2022

Prevision Policy Clips | Oligonucleotide Therapeutics FDA Conference To Feature Principal Deputy Commissioner Janet Woodcock

March 18, 2022

Generic Drug, Manufacturing Reforms Have Some Industry Support As User Fee Ride-Alongs; Details Need Focus

March 17, 2022

PhRMA, BIO Hope To Fend Off Accelerated Approval Reforms, Diversity Mandates In User Fee Reauthorization; Legislative Tone Stays Positive In House Hearing

March 17, 2022

Parallel Scientific Advice: FDA Sees Greater Opportunity For Sponsors In Underutilized Program With EMA

March 17, 2022

Stuck In The Mud: Senate Drug Pricing Hearing Showcases A Stalemate, Though Wyden Presses For “Hardball Negotiation” In Medicare

March 17, 2022

Prevision Policy Clips | White House COVID Response Coordinator Will Be Brown’s Jha

March 17, 2022

CBER CAR T Research Looking To Decrease Immunogenicity; CBER’s OTAT Expects Internal Investigators To Apply Research To Regulatory Decisions

March 16, 2022

CAR T Product Development Guidance: FDA Recommendations Include Anticipating Manufacturing Changes, Early Assay Development

March 16, 2022

Prevision Policy Clips | FDA Continues To Meet Hiring Goals

March 16, 2022

Gene Editing Draft Guidance: FDA Recommends Staggered Enrollment With Children Last; “Clinically Meaningful” Primary Endpoint A Requirement

March 15, 2022

PREVENT Bill Mark-Up: FDA “Gold Standard” Extolled As Key Lesson Coming Out Of COVID; US Manufacturing Base Remains In Spotlight, LDT Reform Deferred

March 15, 2022

Prevision Policy Clips | FDA Gene Editing, CAR-T Draft Guidances Published March 15

March 15, 2022

Amyloidosis Public-Private Partnership With FDA Working on Multi-Domain Endpoints, Federated Data Analytics Approach

March 14, 2022

FDA Defends Accelerated Approval Follow-Up Process With Data; Is Low Withdrawal Rate A Sign Of A Different Problem?

March 14, 2022
1 2 3 4 5 6 Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Tweets by PrevisionPolicy

Copyright © 2022 Prevision Policy. All Rights Reserved. Privacy Policy